ArticleLiver research (Beijing, China)2026
MND1 protein mediates DNA damage repair and is a promising novel therapeutic target in hepatocellular carcinoma.
Article in Liver research (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need to identify novel therapeutic targets. Bioinformatic analysis initially identified meiotic nuclear division 1 ( Methods: The expression profile of MND1 was validated using data from public databases along with 22 paired clinical HCC specimens. The functional roles of MND1 were investigated through Results: Multi-omics analysis and clinical validation revealed that MND1 is overexpressed in HCC tissues and significantly correlates with poor prognosis. Comprehensive Conclusions: These findings suggest that MND1 may serve as both a potential molecular marker and an oncogenic contributor in HCC. Importantly, the newly identified MND1-TRIM28-DDR regulatory axis offers a promising rationale for the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.